Davis's Drug Guide
Special Dosing Considerations
General
For many patients the average dose range for a given drug can be toxic. The purpose of this section is to describe vulnerable patient populations for which special dosing considerations must be made to protect the patient and improve clinical outcomes.
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Special Dosing Considerations." Davis's Drug Guide, 19th ed., F.A. Davis Company, 2025. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/109953/all/Special_Dosing_Considerations.
Vallerand AHA, Sanoski CAC, . Special Dosing Considerations. Davis's Drug Guide. F.A. Davis Company; 2025. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/109953/all/Special_Dosing_Considerations. Accessed May 18, 2025.
Vallerand, A. H., Sanoski, C. A., & , (2025). Special Dosing Considerations. In Davis's Drug Guide (19th ed.). F.A. Davis Company. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/109953/all/Special_Dosing_Considerations
Vallerand AHA, Sanoski CAC, . Special Dosing Considerations [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2025. [cited 2025 May 18]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/109953/all/Special_Dosing_Considerations.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Special Dosing Considerations
ID - 109953
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - ,,
BT - Davis's Drug Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/109953/all/Special_Dosing_Considerations
PB - F.A. Davis Company
ET - 19
DB - Pediatrics Central
DP - Unbound Medicine
ER -
